We are live on
!
Find out more
DnB Asset Management Portfolio holdings
AUM
$28B
1-Year Est. Return
26%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+26%
3 Year Est. Return
+97.1%
5 Year Est. Return
+115.87%
10 Year Est. Return
+443.63%
AUM
$21.7B
AUM Growth
-$1.42B
(-6.1%)
Cap. Flow
+$74.1M
Cap. Flow
% of AUM
0.34%
Top 10 Holdings %
Top 10 Hldgs %
37.96%
Holding
778
New
46
Increased
318
Reduced
356
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$323M |
| 2 |
Oracle
ORCL
|
+$303M |
| 3 |
SNDK
Sandisk
SNDK
|
+$244M |
| 4 |
Marvell Technology
MRVL
|
+$180M |
| 5 |
Booking.com
BKNG
|
+$134M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$355M |
| 2 |
Mastercard
MA
|
+$247M |
| 3 |
Electronic Arts
EA
|
+$222M |
| 4 |
Western Digital
WDC
|
+$221M |
| 5 |
Meta Platforms (Facebook)
META
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.89% |
| 2 | Communication Services | 13.62% |
| 3 | Financials | 12.74% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Healthcare | 9.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Biohaven
BHVN
$2.02B
| $230K | ﹤0.01% |
9,576
+2,050
| +27% | +$72.3K |
|
702
Celldex Therapeutics
CLDX
$2.94B
| $229K | ﹤0.01% |
12,634
+2,503
| +25% | +$55.9K |
|
703
Geron
GERN
$898M
| $217K | ﹤0.01% |
136,581
+44,338
| +48% | +$108K |
|
704
Janux Therapeutics
JANX
$912M
| $210K | ﹤0.01% |
7,765
+1,987
| +34% | +$74.9K |
|
705
Vera Therapeutics
VERA
$2.33B
| $204K | ﹤0.01% |
+8,485
| New | +$273K |
|
706
Microbot Medical
MBOT
$112M
| $173K | ﹤0.01% |
+114,821
| New | +$203K |
|
|
RBOT
707
DELISTED
Vicarious Surgical
RBOT
| $171K | ﹤0.01% |
26,045
+4,832
| +23% | +$57.1K |
|
708
Compañía de Minas Buenaventura
BVN
$7.68B
| $162K | ﹤0.01% |
10,387
| – | – |
|
709
LanzaTech
LNZA
$59.9M
| $160K | ﹤0.01% |
6,625
+3,242
| +96% | +$292K |
|
710
AGNC Investment
AGNC
$12.7B
| $156K | ﹤0.01% |
+16,332
| New | +$163K |
|
|
SERV
711
Serve Robotics
SERV
$372M
| $152K | ﹤0.01% |
26,453
+5,097
| +24% | +$66.9K |
|
712
Arbe Robotics
ARBE
$73.3M
| $149K | ﹤0.01% |
144,840
+15,098
| +12% | +$33.3K |
|
713
Aspen Aerogels
ASPN
$339M
| $148K | ﹤0.01% |
23,126
| – | – |
|
714
Annexon
ANNX
$796M
| $144K | ﹤0.01% |
74,379
+26,714
| +56% | +$88.9K |
|
715
Palladyne AI
PDYN
$228M
| $141K | ﹤0.01% |
+23,957
| New | +$195K |
|
716
Rithm Capital
RITM
$5.58B
| $136K | ﹤0.01% |
+11,861
| New | +$137K |
|
717
Regenxbio
RGNX
$616M
| $132K | ﹤0.01% |
18,491
+3,952
| +27% | +$29.4K |
|
718
Ondas Inc
ONDS
$3.87B
| $126K | ﹤0.01% |
117,617
+87,839
| +295% | +$132K |
|
719
Red Cat Holdings
RCAT
$1.03B
| $105K | ﹤0.01% |
+18,007
| New | +$144K |
|
720
Recursion Pharmaceuticals
RXRX
$1.58B
| $100K | ﹤0.01% |
18,917
-66,448
| -78% | -$484K |
|
721
4D Molecular Therapeutics
FDMT
$502M
| $90K | ﹤0.01% |
27,856
+11,558
| +71% | +$54.5K |
|
722
Rekor Systems
REKR
$82.6M
| $84.5K | ﹤0.01% |
+95,296
| New | +$150K |
|
723
Nauticus Robotics
KITT
$5.28M
| $84.5K | ﹤0.01% |
1,277
+543
| +74% | +$63.9K |
|
|
ABX
724
Abacus Global Management
ABX
$988M
| $79.1K | ﹤0.01% |
+10,556
| New | +$80.1K |
|
725
electroCore
ECOR
$50.4M
| $74.3K | ﹤0.01% |
11,112
| – | – |
|
Similar funds
N
PCH
TWC
FDCDDQ
NA
DnB Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, DnB Asset Management held 778 positions worth $21.7B, down 6.1% from $23.1B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
DnB Asset Management's Q1 2025 filing shows 46 new, 318 increased, 356 reduced and 40 closed positions. Its largest new stake was Sandisk: 4,906,280 shares worth $234M. The largest sale was Visa, an estimated $355M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 34% a quarter earlier, followed by Communication Services and Financials.
- DnB Asset Management's largest Q1 2025 buy was Sandisk: 4,906,280 shares worth $234M.
- DnB Asset Management added most to NVIDIA in Q1 2025, an estimated $323M increase.
- DnB Asset Management's biggest Q1 2025 reduction was Visa, cutting an estimated $355M.
- DnB Asset Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $7.31M.
- DnB Asset Management's ten largest holdings make up 38% of its $21.7B portfolio in Q1 2025.
- DnB Asset Management opened 46 new positions and closed 40 in Q1 2025.
- DnB Asset Management's portfolio value fell 6.1% quarter-over-quarter to $21.7B.
Based on DnB Asset Management's 13F filing for Q1 2025, filed 15 May 2025.